BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Omaima M. Abbas, Mohamed H. Abdel-Rahman, Nabil A. Omar, Hanaa M. Badran, Elamir M. Amir. Interleukin-10 promoter polymorphisms in hepatitis C patients with and withoutSchistosoma mansonico-infectionLiver International 2009; 29(9): 1422 doi: 10.1111/j.1478-3231.2009.02068.x
2
Ayman A. Abdo, Faisal M. Sanai. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspectsAnnals of Saudi Medicine 2009; 29(1): 1 doi: 10.4103/0256-4947.51810
3
Gasim I Gasim, Abdelhaleem Bella, Ishag Adam. Schistosomiasis, hepatitis B and hepatitis C co-infectionVirology Journal 2015; 12(1): 19 doi: 10.1186/s12985-015-0251-2
4
David J. Riedel, Simone Taylor, Raulina Simango, Athanase Kiromera, Jackson Sebeza, Cyprien Baribwira, Emmanuel Musabeyezu. Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda: Table 1.Transactions of The Royal Society of Tropical Medicine and Hygiene 2016; 110(8): 495 doi: 10.1093/trstmh/trw055
5
A. Elsharkawy, R. Fouad, W. El Akel, M. El Raziky, M. Hassany, G. Shiha, M. Said, I. Motawea, T. El Demerdash, S. Seif, A. Gaballah, Y. El Shazly, M. A. M. Makhlouf, I. Waked, A. O. Abdelaziz, A. Yosry, M. El Serafy, M. Thursz, W. Doss, G. Esmat. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in EgyptAlimentary Pharmacology & Therapeutics 2017; 45(5): 681 doi: 10.1111/apt.13923
6
Rosario González-Casas, María Trapero-Marugán, Ricardo Moreno-Otero. Hepatitis crónica por virus de la hepatitis C genotipo 4Medicina Clínica 2011; 137(1): 31 doi: 10.1016/j.medcli.2010.03.022
7
Hamad I. Al-Ashgar, Mohammed Q. Khan, Ahmed Helmy, Sahar Al-Thawadi, Mohammed N. Al-Ahdal, Nisreen Khalaf, Ahmed Al-Qahtani, Faisal M Sanai. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4European Journal of Gastroenterology & Hepatology 2013; 25(4): 404 doi: 10.1097/MEG.0b013e32835bc2cf
8
Maissa El Raziky, Waleed Fouad Fathalah, Zeinab Zakaria, Hadeel Gamal Eldeen, Amr Abul-Fotouh, Ahmed Salama, Abubakr Awad, Gamal Esmat, Mahasen Mabrouk. Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining TechniquesJournal of Interferon & Cytokine Research 2016; 36(5): 338 doi: 10.1089/jir.2015.0141
9
Gamal El Din Esmat Gamil, Maissa El Said El Raziky, Rabab Maamoun Salama, Wafaa Ahmed El Akel, Waleed Fouad Fathalah, Dina Ismail Attia. Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4Advances in Infectious Diseases 2013; 3(02): 78 doi: 10.4236/aid.2013.32012
10
Sharif B. Missiha, Mario Ostrowski, E. Jenny Heathcote. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable FactorsGastroenterology 2008; 134(6): 1699 doi: 10.1053/j.gastro.2008.02.069
11
Leonard B. Seeff. The history of the “natural history” of hepatitis C (1968-2009)Liver International 2009; 29: 89 doi: 10.1111/j.1478-3231.2008.01927.x
12
Brittany E. Yee, Nghia H. Nguyen, Bing Zhang, Philip Vutien, Carrie R. Wong, Glen A. Lutchman, Mindie H. Nguyen. Meta-analysisEuropean Journal of Gastroenterology & Hepatology 2014; 26(11): 1189 doi: 10.1097/MEG.0000000000000147
13
Sanaa M. Kamal. Hepatitis C genotype 4 therapy: increasing options and improving outcomesLiver International 2009; 29: 39 doi: 10.1111/j.1478-3231.2008.01930.x
14
Okba Haj-Ali Saflo, Jesús Miguel Hernández Guijo. Coste-eficacia del tratamiento de la hepatitis C crónica en EspañaGastroenterología y Hepatología 2009; 32(7): 472 doi: 10.1016/j.gastrohep.2009.01.181
15
Vasilios Papastergiou, Stylianos Karatapanis. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6World Journal of Clinical Cases 2015; 3(3): 210-220 doi: 10.12998/wjcc.v3.i3.210
16
Hamad Al Ashgar, Ahmed Helmy, Mohamed Q. Khan, Khalid Al Kahtani, Mohammed Al Quaiz, Mohammed Rezeig, Ingvar Kagevi, Abdullah Alshehri, Abdullah Al Kalbani, Khalid Al Swat, Salim Dahab, Naser Elkum, Mohammed Al Fadda. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4Annals of Saudi Medicine 2009; 29(1): 4 doi: 10.4103/0256-4947.51816
17
Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud, Lise Lotte Gluud. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CCochrane Database of Systematic Reviews 2014;  doi: 10.1002/14651858.CD005441.pub3
18
H.M. Dabbous, M.S. Elmeteini, M.A. Sakr, I.F. Montasser, M. Bahaa, A. Abdelaal, M. Fathy, R. Refaie, M. Seyam, A. Abdelmonem, A. Mukhtar, N. Hegazy, M. Almoneiri. Optimizing Outcome of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplantation: Moving Forward by Looking BackTransplantation Proceedings 2014; 46(3): 822 doi: 10.1016/j.transproceed.2013.11.152
19
Tahany Awad, Kristian Thorlund, Mahasen Mabrouk, Christian Gluud. Hepatitis C intervention research – Where are we now and where should we be heading?Arab Journal of Gastroenterology 2009; 10(1): 4 doi: 10.1016/j.ajg.2009.03.005
20
Sanaa M. Kamal, Imad A. Nasser. Hepatitis C genotype 4: What we know and what we don't yet knowHepatology 2008; 47(4): 1371 doi: 10.1002/hep.22127
21
Mohamed Elashri, Farag M. Farag, Nader El-Malky, Elsayed Abd Elmaksood, Mohammed Elarman. Serum level of interleukin-8 and interleukin-10 as predictors for response to interferon–ribavirin combined therapyEgyptian Liver Journal 2016; 6(1): 7 doi: 10.1097/01.ELX.0000481902.94221.61
22
Mahmoud A. Khattab, Peter Ferenci, Stephanos J. Hadziyannis, Massimo Colombo, Michael P. Manns, Piero L. Almasio, Rafael Esteban, Ayman A. Abdo, Stephen A. Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S. Lee. Management of hepatitis C virus genotype 4: Recommendations of An International Expert PanelJournal of Hepatology 2011; 54(6): 1250 doi: 10.1016/j.jhep.2010.11.016
23
Sanaa M. Kamal. Advanced Therapy for Hepatitis C2011; : 113 doi: 10.1002/9781444346343.ch15
24
Shirin Mirza, Amna Rehana Siddiqui, Saeed Hamid, Muhammad Umar, Shaheena Bashir. Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort studyBMC Gastroenterology 2012; 12(1) doi: 10.1186/1471-230X-12-71
25
Gamal Esmat, Mohamed El Kassas, Mohamed Hassany, Mohamed Gamil, Maissa El Raziky. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continuesLiver International 2014; 34: 24 doi: 10.1111/liv.12397
26
M. F. Derbala, N. Z. El Dweik, S. R. Al Kaabi, A. D. Al-Marri, F. Pasic, A. B. Bener, F. M. Shebl, A. M. Amer, M. T. Butt, R. Yakoob, A. John, M. Al Mohanadi, M. A. Al Khinji. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapyJournal of Viral Hepatitis 2008; 15(8): 591 doi: 10.1111/j.1365-2893.2008.00988.x
27
Brittany E Yee, Nghia H Nguyen, Bing Zhang, Derek Lin, Philip Vutien, Carrie R Wong, Glen A Lutchman, Mindie H Nguyen. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysisBMJ Open Gastroenterology 2015; 2(1): e000049 doi: 10.1136/bmjgast-2015-000049
28
Vasilios Papastergiou, Dimitrios Dimitroulopoulos, Lamprini Skorda, Philippos Lisgos, Ioannis Ketikoglou, Nikolaos Kostas, Stylianos Karatapanis. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?Journal of Medical Virology 2012; 84(8): 1217 doi: 10.1002/jmv.23324
29
Nabil Antaki, Antonio Craxi, Sanaa Kamal, Rami Moucari, Schalk Van der Merwe, Samir Haffar, Adrian Gadano, Nizar Zein, Ching Lung Lai, Jean-Michel Pawlotsky, E. Jenny Heathcote, Geoffrey Dusheiko, Patrick Marcellin. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus reportLiver International 2010; 30(3): 342 doi: 10.1111/j.1478-3231.2009.02188.x
30
Abdulrahman A. Aljumah, Mohammad Hassan Murad. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysisHepatology Research 2013; 43(12): 1255 doi: 10.1111/hepr.12084
31
Jarrod Bailey. An Assessment of the Use of Chimpanzees in Hepatitis C Research Past, Present and Future: 2. Alternative Replacement MethodsAlternatives to Laboratory Animals 2010; 38(6): 471 doi: 10.1177/026119291003800602
32
Menka M. Sanghvi, Peter J. Hotez, Alan Fenwick. Neglected tropical diseases as a cause of chronic liver disease: the case of Schistosomiasis and Hepatitis C Co-infections in EgyptLiver International 2013; 33(2): 165 doi: 10.1111/liv.12052